Adherence to Medical Cannabis Among Licensed Patients in Israel

Zolotov, Yuval; Baruch, Yehuda; Reuveni, Haim; Magnezi, Racheli

doi:10.1089/can.2015.0003

Cited by 9 publications

(7 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Israel, one cross-sectional study examined factors associated with the extent to which a patient takes MM as prescribed among those with a MM license (Zolotov et al, 2016). Patient’s level of participation in their healthcare (AOR=1.13, 95% CI: 1.03–1.24) and patients’ perceived relationship between them and their physician (AOR=1.40, 95% CI: 1.11–1.77) were positively associated with adherence to MMU.…”

Section: Resultsmentioning

confidence: 99%

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Park

2017

Drug and Alcohol Dependence

131

View full text Add to dashboard Cite

Background The use of marijuana for medical purposes is now legal in some U.S. states and other jurisdictions, such as Canada, and Israel. Despite the widespread legalization of medical marijuana globally, there is limited information on patterns and correlates of medical marijuana use (MMU). We conducted a literature review to assess prevalence, reasons, perceived effects, and correlates of MMU among adolescents and adults. Methods We searched peer-reviewed articles in English between January 1996 and August 2016 from several databases (PubMed, Google Scholar, Embase, CINAHL, and PsycINFO) using different combinations of keywords. Results A total of 25 articles met the inclusion criteria. In the U.S., national survey estimates of prescribed MMU was 1.1% among 12th graders and 17% among adults who reported past-year marijuana use. The reported prevalence of prescribed MMU ranged from <1.7% in Israeli cancer patients to 17.4% in American health care patients. The reported prevalence of self-medication with marijuana ranged from 15% in Canadian patients with chronic pain to 30% in British patients with multiple sclerosis. Pain was the most frequently endorsed reason for use. MMU appeared to provide symptom relief for a range of pain conditions, sleep disturbance, and anxiety symptoms, but it did not appear to provide sufficient relief of cluster headache symptoms. Non-medical marijuana use was a common factor associated with MMU across studies. Conclusion Either MMU or self-medication with marijuana was common, mainly due to pain management. Additional research is needed to evaluate temporal and causal associations of non-medical marijuana use with MMU.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Park

2017

Drug and Alcohol Dependence

131

View full text Add to dashboard Cite

show abstract

“…The patient–physician relationship and patient activation were associated with medical cannabis adherence and predicted better health outcomes and health behaviors. 31 Data on adherence to medical cannabis treatment could inform treatment outcomes and effectiveness.…”

Section: Discussionmentioning

confidence: 99%

Authorization Patterns, Safety, and Effectiveness of Medical Cannabis in Quebec

Kalaba¹,

Peters²,

Eglit³

et al. 2021

Cannabis and Cannabinoid Research

View full text Add to dashboard Cite

Introduction: Despite increasing demand for data, little is known about the authorization patterns, safety, and effectiveness of medical cannabis products. Materials and Methods: We conducted a 2 year observational study of adult patients who were legally authorized a medical cannabis product from a single licensed producer; we captured and analyzed authorized cannabis use patterns by cannabinoid profile (tetrahydrocannabinol [THC]-dominant; cannabidiol [CBD]-dominant; and balanced (THC:CBD) and clinical outcomes using standardized outcome measures every 3 months for 12 months at a network of medical cannabis clinics in Quebec, Canada. Results: We recruited 585 patients (average age 56.5 years), of whom 61% identified as female and 85% reported pain as their primary complaint. Over 12 months, there was a significant increase in the number of products authorized (Z = 2.59, p = 0.01). The proportion of authorizations for a THC-dominant or CBD-dominant product increased relative to the proportion of authorizations for a balanced (THC:CBD) product (all p < 0.01). Symptom improvement over time was observed for pain, tiredness, drowsiness, anxiety, and well-being. Patients authorized THC-dominant products exhibited less symptom improvement for anxiety and well-being relative to those authorized CBD-dominant or balanced (THC:CBD) products. Medical cannabis was well tolerated across all product profiles. Conclusion: These real-world data reveal changes in medical cannabis authorization patterns and suggest that symptom improvement may vary by cannabinoid profile over 12 months of follow-up.

show abstract

“…This aspect is also important because it has been found that experiencing a cannabis‐related AE (i.e. dizziness, fatigue, mild anxiety and feeling “weird”) is more common among nonadhering patients than among adhering ones . Thus, improving patients' education on cannabis treatments, could improve their therapy compliance, and reduce nonadherence affects, in particular psychiatric and nervous system AEs.…”

Section: Discussionmentioning

confidence: 99%

Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database

Crescioli

Lombardi

Bettiol

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims: Despite a significant increase in using cannabis for medical purposes, current evidence on its safety in real-world clinical practice is still poorly characterised. By a case-by-case analysis of spontaneous reports of suspected adverse events (AEs) collected in Tuscany within the Italian Phytovigilance database, the aim of the present study was to describe AEs occurred in patients exposed to medical cannabis. Methods: We evaluated all reports of cannabis-related suspected AEs collected within the Phytovigilance database up to December 2018. Information regarding cannabis therapy, patient's demographic and clinical characteristics, concomitant medications, AE description according to the Medical Dictionary for Regulatory Activities (MedDRA) classification, AE seriousness and AE outcome, were collected. The causality assessment was performed following World Health Organisation-Uppsala Monitoring Centre criteria.Results: Fifty-three cannabis-related AE reports were analysed. The majority of patients were females (77.3%), with a mean age of 61.9 years. Thirty-nine (73.6%) cases were defined as nonserious and the majority of them (86.9%) showed a complete resolution or improvement. Forty-six (86.8%) cases were judged as probably related to cannabis consumption. The most frequently reported system organ class was psychiatric and nervous system disorders, and a potential drug-drug interaction was present in 16 cases. Conclusion:Cannabis was generally well tolerated and the majority of AEs were mild and transient. Our analysis highlighted important safety issues for clinical practice, in particular the need for an accurate prescription monitoring during the titration phase, particularly in the presence of concomitant medications. K E Y W O R D Sadverse drug reactions, clinical pharmacology, drug safety, general practice, medical cannabis Giada Crescioli and Niccolò Lombardi are co-first authors.

show abstract

Adherence to Medical Cannabis Among Licensed Patients in Israel

Cited by 9 publications

References 52 publications

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Authorization Patterns, Safety, and Effectiveness of Medical Cannabis in Quebec

Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database

Contact Info

Product

Resources

About